+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Foscarnet Sodium Market - Global Forecast 2026-2032- Product Image
Foscarnet Sodium Market - Global Forecast 2026-2032- Product Image
Sale

Foscarnet Sodium Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6119099
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Foscarnet Sodium Market is projected to reach USD 354.27 Million in 2026. It is expected to continue growing at a CAGR of 7.30%, reaching USD 540.21 Million by 2032.

Foscarnet Sodium: Executive Summary and Market Context

Foscarnet sodium is an antiviral medicine used primarily when infections caused by herpesviruses, including resistant cytomegalovirus and acyclovir-resistant herpes simplex virus, require an alternative treatment approach. Its clinical value is closely linked to specialist infectious-disease care, hospital formularies, diagnostic confirmation, and monitoring of renal function and electrolytes. Because treatment can involve significant toxicity and intravenous administration, adoption depends less on broad outpatient use and more on clinical need, treatment guidelines, supply reliability, and institutional expertise.

Specialist Care and Resistance Are Reshaping Foscarnet Sodium Use

The landscape is being reshaped by antimicrobial resistance, immunocompromised patient populations, transplantation, oncology care, and advances in viral diagnostics. Foscarnet sodium remains relevant where resistance or intolerance limits more commonly used antivirals, but its use requires careful patient selection because nephrotoxicity and electrolyte disturbances can complicate therapy. Health systems are therefore emphasizing stewardship, laboratory confirmation, renal-dose assessment, hydration protocols, adverse-event surveillance, and clear transition plans when alternative therapies become appropriate.

Artificial Intelligence Strengthens Diagnosis, Monitoring, and Stewardship

Artificial intelligence can support the foscarnet sodium care pathway by helping identify patients at risk of resistant viral infection, interpreting longitudinal laboratory results, flagging renal-function deterioration, and assisting clinicians with medication-review workflows. Predictive tools may also improve prioritization of confirmatory testing and support antimicrobial-stewardship audits. However, AI should remain an assistive layer: clinical decisions require validated evidence, transparent reasoning, protection of patient data, and specialist oversight, particularly when treatment involves high-risk toxicity and complex immunocompromised populations.

Regional Insights: Access Depends on Specialist Infrastructure and Diagnostics

North America benefits from comparatively developed transplant, oncology, infectious-disease, and laboratory networks, while formulary controls and safety monitoring shape use. Europe emphasizes guideline-based prescribing, pharmacovigilance, and coordinated health-system procurement. Asia-Pacific presents diverse conditions, combining advanced tertiary-care capacity in some settings with access and diagnostic constraints in others. Latin America faces uneven availability of specialist services, laboratory testing, and hospital medicines. The Middle East shows concentrated expertise in major medical centers alongside differences in procurement and referral capacity. Africa’s use is particularly influenced by access to tertiary care, virology testing, renal monitoring, and dependable medicine supply.

Group Insights: Policy Alignment and Procurement Shape Availability

Within ASEAN, differences in hospital capacity, registration, and laboratory access influence treatment pathways. BRICS members combine large and diverse healthcare systems, making national procurement, specialist referral, and local manufacturing policy important considerations. The European Union benefits from regulatory coordination while retaining substantial variation among national reimbursement and hospital-procurement systems. G7 countries generally have mature clinical infrastructure and pharmacovigilance practices, although stewardship and budget controls remain relevant. GCC states often concentrate complex care in advanced referral centers, while NATO members reflect varied health systems but commonly emphasize preparedness, resilient supply chains, and specialist clinical coordination.

Country Insights: National Capacity Creates Distinct Treatment Pathways

Australia and Canada rely on specialist hospital networks and structured access pathways. Brazil and Mexico must navigate regional differences in tertiary care, procurement, and laboratory coverage. China and India combine advanced urban centers with substantial geographic variation in access. France, Germany, Italy, Spain, and the United Kingdom generally have established infectious-disease services, though reimbursement, formulary, and procurement processes differ. Japan and South Korea have sophisticated hospital and diagnostic systems with strong attention to medication safety. Russia’s treatment environment is shaped by institutional capacity, regulatory processes, and supply-chain conditions. The United States has extensive specialist infrastructure, but access is influenced by hospital formularies, payer arrangements, and availability of monitored inpatient care.

Industry Priorities: Protect Safety, Access, and Evidence Quality

Industry leaders should prioritize dependable supply, clear clinical-use information, and collaboration with infectious-disease, transplant, oncology, and pharmacy specialists. Evidence-generation programs should focus on resistant infections, real-world safety, renal and electrolyte monitoring, and outcomes in immunocompromised populations. Organizations can strengthen responsible use through diagnostic partnerships, clinician education, stewardship support, and standardized hydration and laboratory protocols. Digital tools should be introduced only after clinical validation and should complement-not replace-specialist judgment. Regional strategies should account for registration requirements, procurement structures, cold-chain or distribution needs where applicable, and differences in hospital capability.

Research Methodology: Evidence-Based Review of Clinical and Health-System Drivers

This executive summary uses the supplied market scope for foscarnet sodium and synthesizes verified, non-estimative insights from established clinical, regulatory, pharmacovigilance, and health-system considerations. The assessment examines therapeutic use, resistance patterns, safety requirements, diagnostic infrastructure, access conditions, procurement, and the potential role of artificial intelligence. Regional, group, and country observations are framed qualitatively and avoid market sizing, shares, forecasts, or unsupported numerical claims. Any investment or operational decision should be supplemented with current product labeling, treatment guidelines, regulatory records, procurement data, and local clinical evidence.

Conclusion: Foscarnet Sodium Remains a High-Value Specialist Option

Foscarnet sodium occupies an important but focused role in antiviral care when resistance or intolerance narrows treatment choices. Its future use will depend on responsible stewardship, early resistance detection, renal and electrolyte monitoring, reliable hospital access, and specialist coordination. Differences across regions, economic groups, and countries make locally adapted implementation essential. Leaders who combine supply resilience, evidence-based education, diagnostic capability, and carefully governed digital tools will be better positioned to support safe and appropriate treatment.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Foscarnet Sodium Market, by Indication
7.1. Introduction
7.2. Cytomegalovirus Retinitis
7.3. Ganciclovir Resistant Cytomegalovirus Infection
8. Foscarnet Sodium Market, by Patient Type
8.1. Introduction
8.2. Aids Patients
8.3. Immunocompromised Patients
8.4. Transplant Patients
9. Foscarnet Sodium Market, by Dosage Form
9.1. Introduction
9.2. Injection
9.3. Solution
10. Foscarnet Sodium Market, by Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Foscarnet Sodium Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Foscarnet Sodium Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Retail Pharmacies
12.5. Specialty Centers
13. Foscarnet Sodium Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Foscarnet Sodium Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Foscarnet Sodium Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Alembic Pharmaceuticals Limited
17.2. AstraZeneca PLC
17.3. Aurobindo Pharma Limited
17.4. Cipla Limited
17.5. Dr. Reddy's Laboratories Ltd.
17.6. Fresenius Kabi AG
17.7. Glenmark Pharmaceuticals Ltd.
17.8. Hetero Drugs Limited
17.9. Hikma Pharmaceuticals PLC
17.10. Lupin Limited
17.11. Mylan N.V.
17.12. Novartis AG
17.13. Pfizer Inc.
17.14. Strides Pharma Science Limited
17.15. Sun Pharmaceutical Industries Ltd.
17.16. Teva Pharmaceutical Industries Ltd.
17.17. Zydus Cadila
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Foscarnet Sodium Market, Years Considered for the Study
FIGURE 2. Global Foscarnet Sodium Market, Research Design
FIGURE 3. Global Foscarnet Sodium Market, Research Framework
FIGURE 4. Global Foscarnet Sodium Market, Data Triangulation
FIGURE 5. Global Foscarnet Sodium Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Foscarnet Sodium Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Foscarnet Sodium Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Foscarnet Sodium Market Size, by Patient Type, 2025 vs 2032 (%)
FIGURE 9. Global Foscarnet Sodium Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Foscarnet Sodium Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global Foscarnet Sodium Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Foscarnet Sodium Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Foscarnet Sodium Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Foscarnet Sodium Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Foscarnet Sodium Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Foscarnet Sodium Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Foscarnet Sodium Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Foscarnet Sodium Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Foscarnet Sodium Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Foscarnet Sodium Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Foscarnet Sodium Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Foscarnet Sodium Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Foscarnet Sodium Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Foscarnet Sodium Market Segmentation & Coverage
TABLE 2. Global Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 3. Global Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Cytomegalovirus Retinitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cytomegalovirus Retinitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cytomegalovirus Retinitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Ganciclovir Resistant Cytomegalovirus Infection Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Ganciclovir Resistant Cytomegalovirus Infection Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Ganciclovir Resistant Cytomegalovirus Infection Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 11. Global Aids Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Aids Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Aids Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Immunocompromised Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Immunocompromised Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Immunocompromised Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Transplant Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Transplant Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Transplant Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 21. Global Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Solution Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Solution Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Solution Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 28. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 38. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 48. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Foscarnet Sodium Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Foscarnet Sodium Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. North America Foscarnet Sodium Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. North America Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 70. North America Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 71. North America Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 72. North America Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 73. North America Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. North America Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. Latin America Foscarnet Sodium Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Latin America Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 77. Latin America Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 78. Latin America Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 79. Latin America Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 80. Latin America Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 81. Latin America Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 82. Europe Foscarnet Sodium Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Europe Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 84. Europe Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 85. Europe Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 86. Europe Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 87. Europe Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Europe Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Middle East Foscarnet Sodium Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Middle East Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. Middle East Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 92. Middle East Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 93. Middle East Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 94. Middle East Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Middle East Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. Africa Foscarnet Sodium Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Africa Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 98. Africa Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 99. Africa Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 100. Africa Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 101. Africa Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Africa Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. Global Foscarnet Sodium Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. ASEAN Foscarnet Sodium Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. ASEAN Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. ASEAN Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 107. ASEAN Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 108. ASEAN Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 109. ASEAN Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. ASEAN Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. GCC Foscarnet Sodium Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. GCC Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 113. GCC Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 114. GCC Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 115. GCC Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 116. GCC Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. GCC Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. European Union Foscarnet Sodium Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. European Union Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 120. European Union Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 121. European Union Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 122. European Union Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 123. European Union Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. European Union Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. BRICS Foscarnet Sodium Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. BRICS Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 127. BRICS Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 128. BRICS Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 129. BRICS Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 130. BRICS Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. BRICS Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. G7 Foscarnet Sodium Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. G7 Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. G7 Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 135. G7 Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 136. G7 Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 137. G7 Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. G7 Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. NATO Foscarnet Sodium Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. NATO Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 141. NATO Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 142. NATO Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 143. NATO Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 144. NATO Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. NATO Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. Global Foscarnet Sodium Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. United States Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 148. United States Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 149. United States Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 150. United States Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 151. United States Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 152. United States Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. United States Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. Canada Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 155. Canada Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. Canada Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 157. Canada Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 158. Canada Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 159. Canada Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Canada Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. Mexico Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 162. Mexico Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 163. Mexico Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 164. Mexico Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 165. Mexico Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 166. Mexico Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Mexico Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. Brazil Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 169. Brazil Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. Brazil Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 171. Brazil Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 172. Brazil Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 173. Brazil Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. Brazil Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. United Kingdom Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 176. United Kingdom Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. United Kingdom Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 178. United Kingdom Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 179. United Kingdom Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 180. United Kingdom Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. United Kingdom Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Germany Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 183. Germany Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 184. Germany Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 185. Germany Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 186. Germany Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 187. Germany Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Germany Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. France Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 190. France Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 191. France Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 192. France Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 193. France Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 194. France Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. France Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. Russia Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 197. Russia Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 198. Russia Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 199. Russia Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 200. Russia Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 201. Russia Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Russia Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Italy Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 204. Italy Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. Italy Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 206. Italy Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 207. Italy Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 208. Italy Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Italy Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 210. Spain Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 211. Spain Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. Spain Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 213. Spain Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 214. Spain Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 215. Spain Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Spain Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. China Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 218. China Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 219. China Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 220. China Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 221. China Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 222. China Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. China Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. India Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 225. India Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. India Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 227. India Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 228. India Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 229. India Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. India Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 231. Japan Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 232. Japan Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. Japan Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 234. Japan Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 235. Japan Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 236. Japan Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. Japan Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. Australia Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 239. Australia Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. Australia Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 241. Australia Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 242. Australia Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 243. Australia Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Australia Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. South Korea Foscarnet Sodium Market Size, 2017-2032 (USD Million)
TABLE 246. South Korea Foscarnet Sodium Market Size, by Indication, 2017-2032 (USD Million)
TABLE 247. South Korea Foscarnet Sodium Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 248. South Korea Foscarnet Sodium Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 249. South Korea Foscarnet Sodium Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 250. South Korea Foscarnet Sodium Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. South Korea Foscarnet Sodium Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. Global Foscarnet Sodium Market Share, by Key Player, 2025
TABLE 253. Global Foscarnet Sodium Market, Key Experts

Companies Mentioned

  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

Related Topics

Related Reports

Cytomegalovirus (CMV) Treatment - Global Strategic Business Report - Product Image

Cytomegalovirus (CMV) Treatment - Global Strategic Business Report

  • Report
  • 384 Pages
  • Global
From
Cytomegalovirus Treatment Drugs Market - Global Forecast 2026-2032 - Product Image

Cytomegalovirus Treatment Drugs Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
CEEC Cytomegalovirus Treatment Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Image

CEEC Cytomegalovirus Treatment Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • 100 Pages
  • Global
From
Cytomegalovirus Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2032 - Product Image

Cytomegalovirus Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2032

  • Report
  • 255 Pages
  • Global
From
Encephalitis Treatment Market - Global Forecast 2026-2032 - Product Image

Encephalitis Treatment Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From

About the Foscarnet Sodium Market

Foscarnet Sodium is a drug used to treat infections caused by viruses, including herpes simplex virus, cytomegalovirus, and HIV. It is a type of antiviral medication that works by blocking the activity of an enzyme called DNA polymerase, which is essential for the replication of the virus. Foscarnet Sodium is administered intravenously and is used in combination with other antiviral medications to treat infections that are resistant to other drugs. It is also used to prevent cytomegalovirus infections in people with weakened immune systems. Foscarnet Sodium is a niche market within the larger Infectious Diseases Drugs market. It is used to treat a limited number of infections, and is typically used in combination with other antiviral medications. As such, it is not a widely used drug, but it is an important treatment option for those who need it. Companies in the Foscarnet Sodium market include GlaxoSmithKline, Merck, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.